RAAB MICHAEL 4

What Happened

• Michael Raab, a director of Amicus Therapeutics (FOLD), disposed of 115,857 shares of common stock on 2026-04-27 for $14.50 per share, generating $1,679,927. Those 115,857 shares consisted of 95,443 common shares and 20,414 restricted stock units that vested at closing of the merger with BioMarin Pharmaceutical Inc.
• In addition, multiple option-related positions (totaling 303,630 underlying shares) were cancelled and converted into cash payments under the merger terms. The cash payout for each option equals ( $14.50 less the option exercise price ) times the number of shares subject to the option; the exact cash amounts for those option conversions were not disclosed in the Form 4.
• All reported options were fully vested and vested in full upon consummation of the merger.

Key Details

• Transaction date: 2026-04-27. Sale price for common/RSU shares: $14.50 per share; proceeds reported: $1,679,927.
• Derivative dispositions (options cancelled/cashed out): 20,000; 16,236; 19,473; 18,574; 36,111; 45,423; 30,474; 42,467; 74,872 — totaling 303,630 underlying shares (cash amounts N/A on the filing).
• Shares disposed that were reported as common/RSU: 95,443 common shares + 20,414 RSUs (vested) = 115,857 shares disposed.
• Shares owned after the transaction: not specified in the provided filing excerpt.
• Filing timeliness: no late filing indication provided in the supplied data.
• Transaction code: D (disposition to issuer) — these were merger-related settlements, not open-market trades.

Context

• These were not market purchases but merger consideration and option cash-outs tied to BioMarin's acquisition of Amicus. The options were cancelled and converted into cash rather than being exercised into outstanding shares.
• Such merger-driven dispositions and cashed-out options are typically routine outcomes of an acquisition and do not necessarily indicate the insider’s ongoing view of the company’s future stock performance.